Our findings that PARP1/2 dual inhibitors may lead to bone loss and exacerbate bone metastasis further emphasize the importance of effective biomarkers to predict the sensitivity of PARP inhibitors and the long-term clinical outcome. The gene discussed is PARP1; the disease is bone metastasis.